Table 1 Clinical characteristics of CZP adverse event reports from the FAERS database (Q2 2008–Q4 2024).
From: A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
Characteristics | Case numbers | Case proportion (%) |
|---|---|---|
Number of reports | 78,143 | |
Gender | ||
Male | 17,085 | 21.86 |
Female | 58,172 | 74.44 |
Miss | 2886 | 3.69 |
Age | ||
Median (IQR) | 51.00(36.00,62.00) | |
< 18 | 870 | 1.11 |
18–45 | 14,933 | 19.11 |
45–65 | 16,914 | 21.64 |
65–75 | 5448 | 6.97 |
≥ 75 | 2391 | 3.06 |
Miss | 37,587 | 48.10 |
Reported countries (Top5) | ||
United States | 46,066 | 67.63 |
Canada | 6225 | 9.14 |
United Kingdom | 4668 | 6.85 |
Brazil | 1706 | 2.50 |
Japan | 1697 | 2.49 |
Reporter | ||
Healthcare professionals | 45,251 | 57.90 |
Consumer | 31,800 | 40.69 |
Unknown | 1073 | 1.37 |
Lawyer | 19 | 0.02 |
